HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated with an
aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the …

Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-
regulation of key signaling pathways which control cell growth and survival. In breast cancer …

Purpose Trastuzumab shows clinical activity in human epidermal growth factor receptor 2
(HER-2)–positive early and advanced breast cancer. In the German Breast Group 26/Breast …

Overexpression of erbB2 in breast tumors is associated with poor prognosis and is a target
of receptor-oriented cancer therapy. Trastuzumab (Herceptin), a monoclonal antibody …

Although current breast cancer treatment guidelines limit the use of HER2-blocking agents
to tumors with HER2 gene amplification, recent retrospective analyses suggest that a wider …

Our knowledge on tissue-and disease-specific functions of human genes is rather limited
and highly context-specific. Here, we have developed a method for the comparison of mRNA …

The constitutive activation of signal transducer and activator of transcription 3 (Stat3) is
frequently detected in breast cancer tissues and cell lines. Stat3 has been classified as a …

Discovering robust prognostic gene signatures as biomarkers using genomics data can be
challenging. We have developed a simple but efficient method for discovering prognostic …

Predicting the outcome of cancer therapies using molecular features and clinical
observations is a key goal of cancer biology, which has been addressed comprehensively …

Identification and characterization of cancer stem cells (CSCs) in gastric cancer are difficult
owing to the lack of specific markers and consensus methods. In this study, we show that …